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Abstract: The insulin-like growth factor (IGF) pathway is involved
in the normal control of fetal development, tissue growth, and
metabolism. Two distinct ligands (insulin-like growth factor-1 [IGF-1]
and IGF-2) plus insulin, and two receptors (insulin-like growth
factor receptor-1 [IGF-1R] and the insulin receptor) capable of both
homo- and heteropolymerization mediate the actions of this path-
way. Cellular functions of IGF-regulated signaling are influenced by
the expression of a variety of receptor docking proteins, including
four different insulin receptor substrate proteins. Downstream sig-
naling is primarily through the phosphatidylinositol-3 kinase-Akt
pathway and the mitogen-activated protein kinase pathway, resulting
in increased cell proliferation and apoptosis inhibition. Ligand-
driven activation is influenced by upstream endocrine factors (par-
ticularly for IGF-1), imprinting (for IGF-2), by multiple circulating
and tissue-based IGF-binding proteins/proteases, and by the expres-
sion of the IGF-2 clearance receptor (IGF-2R). Deregulation of IGF
signaling has been described in several cancer types, including both
small cell and non-small cell lung cancer. A number of IGF receptor
inhibitors, including monoclonal antibodies and small molecule
inhibitors are currently undergoing testing in clinical trials as both
monotherapy, and in combination with chemotherapy, or with other
targeted agents. Preliminary results from a randomized phase II trial
of an anti-IGF-1R monoclonal antibody in combination with carbo-
platin/paclitaxel already suggest a potential efficacy benefit from
targeting this pathway in the first line advanced non-small cell lung
cancer setting.
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The insulin-like growth factor (IGF) pathway involveselements of endocrine, paracrine, and autocrine control in
regulating fetal development, growth, and metabolism.1
Growth hormone stimulates production of insulin-like growth
factor-1 (IGF-1) in the liver and peripheral tissues. IGF-1 is
also released locally in response to damage, either directly or
through the action of other factors associated with tissue
responses to damage, including epidermal growth factor,
fibroblast growth factor, and platelet-derived growth factor.1
The related IGF-2 is present in the circulation at two to
three times the levels of IGF-1, and is also produced in the
liver and peripheral tissues, but its production is mostly
controlled through imprinting-mediated gene dosage regula-
tion.2 IGF-1 is particularly important in somatic growth, with
human mutations in IGF-1 producing severe growth retarda-
tion and mental impairment.3 The role of IGF-2 seems to vary
between species. In rodents, IGF-2 has a minor role in
embryonic growth development but little role in adult ani-
mals, in contrast to in humans, where it is the predominant
IGF in adults.2 Both ligands mediate their effects through
activation of the insulin-like growth factor receptor-1 (IGF-
1R), which is highly homologous to the insulin receptor (IR).
Each ligand also has some activity against IR splice variants
(IR-A and IR-B) and/or hybrids of the two receptors (Figure
1). The IGF-1R has a 15- to 20-fold higher affinity for IGF-1
than IGF-2, consistent with its name. Nevertheless, the
greater binding potential of IGF-2 across different receptors
may give it a broader range of biologic functions than IGF-1.
The IGF-2R has no known signal transduction properties and
serves as a clearance receptor for IGF-2.4 The concentration
of free ligands and their exposure kinetics are tightly regu-
lated in the circulation and/or periphery by a range of high-
affinity binding proteins (IGFBP1–6) and their proteases. All
the IGFBPs have a greater affinity than the IGF-receptors for
their ligands. In general, it is difficult to ascribe simple roles
to the IGFBPs as their effects, modulating the kinetics of free
IGF exposure, could in theory, both increase and decrease
IGF-related signaling, depending on the time frame consid-
ered. IGFBP3 is the dominant circulating binding partner for
both IGFs, accounting for 70 to 80% of their blood levels.1,5
IGF-1R may also form hybrid multimeric receptors
with other membrane receptors, for example, the epidermal
growth factor receptor.6 After ligand binding, conformational
changes in the IGF-1R result in activation of its tyrosine
kinase domain, phosphorylation of insulin receptor substrate
proteins (IRS 1–4), and recruitment of a range of docking
proteins The expression of different IRS molecules may be
tissue specific, and may also differentiate various aspects of
the malignant phenotype associated with this pathway, for
example, IRS1 has been associated with proliferation,
whereas IRS2 has been associated with metastatic behav-
ior.7,8 Downstream of the receptors the mitogen-activated
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kinase and phosphatidylinositol-3 kinase-Akt (PI3K-Akt)
pathways become broadly activated, leading to cell prolifer-
ation and inhibition of programmed cell death.
IGF PATHWAY AND LUNG CANCER
Multiple lines of evidence suggest involvement of the
IGF pathway across a range of malignancies, including both
non-small cell lung cancer (NSCLC) and small cell lung
cancer.9–11 Elevated plasma levels of IGF-1 have been asso-
ciated with an increased risk of lung cancer, and high plasma
levels of IGFBP3 associated with a reduced risk.11,12 Simi-
larly, IGFBP3 promoter methylation in tumor cells has been
linked to decreased survival in stage I NSCLC patients.13 A
large case-control study of Whites identified 64 single nucle-
FIGURE 2. Potential therapeutic strategies for
reducing IGF pathway signaling. The dominant
strategies currently being explored in the clinic
are the monoclonal antibodies directed against
the extracellular domain of the receptor, and
small molecule inhibitors of the IGF-1R tyrosine
kinase domain.
FIGURE 1. Schematic representation of the IGF axis at the level of a peripheral tissue. Three different ligands (insulin, IGF-1,
IGF-2) affected by upstream elements of hormonal control (prediminatly IGF-1) and imprinting (IGF-2), six different binding
proteins, three different receptors, and a range of intracellular substrates and docking proteins influence intracellular signaling.
The avidity of the different ligands for the different receptor combinations are shown in the embedded table. Activity in the
pathway is also influenced by pTEN inhibition of the PI3K pathway, and p53-mediated receptor down-regulation, and
therefore mutations in either/both genes may influence a tumor’s dependence on the pathway.
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otide polymorphisms associated with lung cancer risk, of
which 11 were related to the growth hormone-insulin-like
growth factor axis.14 Preclinically, IGF-1R activation acts as
a cofactor for malignant transformation by a number of
different stimuli.15 Transgenic mice engineered to express
constitutively active IGF-1R develop malignant tumors, in-
cluding salivary and mammary adenocarcinomas.16 Nearly
70% of transgenic mice over-expressing IGF-2 develop lung
adenocarcinomas by 18 months of age.17
DEVELOPMENT OF IGF-1R INHIBITORS IN
LUNG CANCER
There are several strategies being explored to disrupt
IGF pathway signaling in cancers (Figure 2).18,19 The two
dominant strategies currently being explored are monoclonal
antibodies directed against the extracellular domain of the
IGF-1R, and small molecule inhibitors of its intracellular
kinase domain. The monoclonal antibodies are further ad-
vanced in clinical development at present and seem to act
primarily through down-regulation of the IGF-1R.20 In con-
trast, the small molecule inhibitors seem to reduce signaling
without requiring receptor internalization.21 Because of direct
effects on IRs, and/or complementary signaling between the
pathways, hyperglycemia (potentially controllable with oral
agents such as metformin) has already been noted and is
anticipated to be a class-specific toxicity. IGF-1R activation
provides a potential mechanism of cell protection to cytotoxic
chemotherapeutics through increased downstream signaling
through the prosurvival PI3K-Akt pathway.22,23 Results of
studies on cell lines and xenografts suggest synergistic activ-
ity of IGF-1R inhibitors with a variety of cytotoxic
agents.24–26 Prolonged treatment of NSCLC cell lines with
low concentrations of erlotinib or gefitinib resulted in ac-
quired resistance mediated by activated IGF-1R with IGF-
1R/epidermal growth factor receptor heterodimer formation
leading to up-regulation of survivin expression.6,27 IGF-1R
activation is also involved in protection from ionizing radia-
tion, and IGF-1R inhibitors increase radiation sensitivity of
NSCLC cell lines.28,29 These findings support the clinical
testing of combinations of IGF-1R inhibitors with both tra-
ditional anticancer therapies (cytotoxics, radiotherapy) and
targeted agents in lung cancer. Phase I monotherapy study
results reported for the monoclonal antibodies CP-751,871,
R1507, AMG 479, and IMC-A12 have shown little in the way
of toxicities, apart from some hyperglycemia and, for some of
the antibodies, thrombocytopenia.30–33 There have been hints
of single agent activity across several different cancer types
in these all-comers studies, but noted dramatic single agent
activity in Ewing sarcoma patients, fast-tracking a range of
subsequent sarcoma-specific phase II studies.32 To date, in
lung cancer, preliminary phase II results of only one anti-
IGF-1R agent have been reported. In a randomized first-line
advanced NSCLC phase II study of paclitaxel and carboplatin
plus/minus CP751,871, 46% of patients in the experimental
arm achieved objective responses (22/48 patients) versus
32% (8/25 patients) in the control arm.31 An unplanned
subgroup analysis by histology has suggested a greater ben-
efit in patients with squamous histology within this trial, but
the results of additional patient numbers, including planned
enrichment for those with squamous histology, are awaited.
CONCLUSIONS
The IGF pathway is implicated in the induction and
maintenance of a range of different malignancies. Its activity
is influenced by a range of different ligands, upstream hor-
monal regulation, imprinting, binding protein and protease
expression, signaling and clearance receptor expression and
hybridization, and intracellular substrate expression. Clinical
data already show a favorable toxicity profile and some
monotherapy activity signals for several anti-IGF-1R mono-
clonal antibodies, whereas little data on the tolerability or
efficacy of the small molecule inhibitors of the IGF-1R are
currently available. Early efficacy signals from a phase II
study of CP-751,871 in combination with carboplatin/pacli-
taxel in advanced NSCLC are promising, however, final
reports of this trial are awaited and several other trials of
anti-IGF-1R antibodies in combination studies in lung cancer
are ongoing. The challenge will inevitably be how to opti-
mally select patients to treat with IGF-1R inhibitors based on
the molecular characteristics of their tumors, and several
correlative studies looking across the range of factors known
to influence activating within this pathway are currently
underway in association with these clinical trials.
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